Senseonics Rolls Out Eversense 365 1-Year CGM in Europe

Senseonics announced the first European launch of its Eversense 365 continuous glucose monitoring (CGM) system.

According to the company, Eversense 365 is the world’s first and only one-year CGM. After January’s CE mark approval, the technology is now available to the first patients in Sweden, with launches to follow in Germany, Spain, and Italy during the coming weeks.

The next-generation Eversense 365 doubles sensor lifespan from the previously available Eversense E3 from six months to a full year. This provides improvements like reducing the frequency of calibrations from once daily to once weekly.

“This launch of Eversense 365 is a significant breakthrough for diabetes technology in Europe and for Senseonics as a business, as we successfully transition to an end-to-end commercial organization this year,” said Senseonics president and CEO Tim Goodnow, Ph.D. “Building on demonstrable commercial momentum in the U.S., European expansion is a key part of our Eversense 365 growth strategy, increasing our total addressable market by over 30 million patients.”

Traditional CGMs last 10-15 days and tend to fail early, the company said. Senseonics’ tiny sensor was designed to rest comfortably under the skin for a full year. Its removable smart transmitter can be taken off and reapplied without wasting a CGM.

The company claimed Eversense 365 has exceptional accuracy for one year, with almost no false alerts from compression lows during sleep. Its gentle, silicone-based adhesives are changed daily and cause almost no skin reactions.

“The excitement for Eversense 365 was palpable at ATTD and we’re thrilled to now offer this life-changing technology to the first patients in Europe,” said Brian Hansem, chief commercial officer of Senseonics. “Real-world evidence showcases Eversense 365’s unique benefits—delivering one year of exceptionally accurate monitoring with minimal interruptions—enabling patients to focus on managing their diabetes and not their CGM.”

In February, Sequel Med Tech and Senseonics announced full availability of the twiist automated insulin delivery (AID) system integrated with the Eversense 365 CGM system in the U.S.